<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004339</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00042-1850</org_study_id>
    <secondary_id>UMMC-801</secondary_id>
    <secondary_id>UMICH-FDU000505</secondary_id>
    <nct_id>NCT00004339</nct_id>
  </id_info>
  <brief_title>Study of Tetrathiomolybdate in Patients With Wilson Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with
      trientine therapy as initial treatment in patients with Wilson disease presenting
      neurologically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This a double blind, randomized study. Patients are randomized into one of
      two treatment arms.

      Arm I: Patients receive tetrathiomolybdate (TM) 3 times a day with meals and 3 times a day
      between meals for 8 weeks in the absence of neurologic deterioration or unacceptable
      toxicity.

      Arm II: Patients receive trientine therapy for 8 weeks in the absence of neurologic
      deterioration and unacceptable toxicity.

      Additional therapy (off study): Patients in the TM group may receive maintenance zinc, while
      those in the trientine group may continue on trientine or switch to zinc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>90</enrollment>
  <condition>Wilson Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetrathiomolybdate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trientine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Wilson disease presenting with neurologic or psychiatric symptoms

          -  No concurrent seizure activity

          -  No white matter lesions on brain magnetic resonance imaging

        --Prior/Concurrent Therapy--

          -  No more than 2 weeks of prior therapy

          -  No penicillamine or trientine for longer than 2 weeks

        --Patient Characteristics--

          -  Hepatic: No severe hepatic failure

          -  Other: No psychiatric or medical contraindication to protocol therapy

          -  Not pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George J. Brewer</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994 Jun;51(6):545-54.</citation>
    <PMID>8198464</PMID>
  </reference>
  <reference>
    <citation>Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996 Oct;53(10):1017-25.</citation>
    <PMID>8859064</PMID>
  </reference>
  <reference>
    <citation>Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr;63(4):521-7.</citation>
    <PMID>16606763</PMID>
  </reference>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>May 8, 2006</last_update_submitted>
  <last_update_submitted_qc>May 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2006</last_update_posted>
  <keyword>Wilson disease</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trientine</mesh_term>
    <mesh_term>Tetrathiomolybdate</mesh_term>
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

